Russell Investments Group
LAB icon

Russell Investments Group’s Standard BioTools LAB Stock Holding History

Russell Investments Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148 Sell
180
-21,454
-99% -$20.3K ﹤0.01% 4252
2026
Q1 		$19.9K Sell
21,634
-3,504
-14% -$4.24K ﹤0.01% 3624
2025
Q4 		$32.2K Buy
25,138
+117
+0.5% +$157 ﹤0.01% 3466
2025
Q3 		$32.5K Buy
25,021
+24,211
+2,989% +$31.7K ﹤0.01% 3434
2025
Q2 		$972 Buy
+810
New +$898 ﹤0.01% 3671
2025
Q1 		– Sell
-220
Closed -$385 – 3840
2024
Q4 		$385 Hold
220
– – ﹤0.01% 3633
2024
Q3 		$425 Hold
220
– – ﹤0.01% 3585
2024
Q2 		$389 Hold
220
– – ﹤0.01% 3518
2024
Q1 		$596 Buy
+220
New +$531 ﹤0.01% 3186
2020
Q4 		– Sell
-106,289
Closed -$788K – 3124
2020
Q3 		$788K Sell
106,289
-1,324,628
-93% -$9.14M ﹤0.01% 2169
2020
Q2 		$5.74M Sell
1,430,917
-5,840,328
-80% -$20.3M 0.01% 1019
2020
Q1 		$18.5M Buy
7,271,245
+1,411,413
+24% +$4.64M 0.05% 430
2019
Q4 		$20.4M Buy
5,859,832
+1,850,282
+46% +$6.51M 0.04% 536
2019
Q3 		$18.6M Sell
4,009,550
-1,428,479
-26% -$11.3M 0.04% 568
2019
Q2 		$67M Sell
5,438,029
-149,060
-3% -$1.9M 0.13% 192
2019
Q1 		$74.2M Buy
5,587,089
+423,877
+8% +$4.47M 0.14% 164
2018
Q4 		$44.5M Buy
5,163,212
+889,727
+21% +$6.93M 0.1% 231
2018
Q3 		$32M Sell
4,273,485
-121,465
-3% -$863K 0.06% 366
2018
Q2 		$26.2M Buy
4,394,950
+684,781
+18% +$3.9M 0.05% 417
2018
Q1 		$21.7M Sell
3,710,169
-121,070
-3% -$795K 0.04% 574
2017
Q4 		$23.6M Buy
3,831,239
+383,748
+11% +$2.1M 0.04% 565
2017
Q3 		$17.4M Buy
3,447,491
+1,099,072
+47% +$4.62M 0.03% 693
2017
Q2 		$9.48M Buy
2,348,419
+89,482
+4% +$424K 0.02% 942
2017
Q1 		$12.8M Buy
2,258,937
+19,725
+0.9% +$125K 0.02% 745
2016
Q4 		$16.1M Buy
+2,239,212
New +$14.1M 0.03% 641

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Russell Investments Group's LAB Position: Q2 2026 in Review

Russell Investments Group reduced its Standard BioTools (LAB) stake by 99% in Q2 2026, selling an estimated $20.3K and leaving 180 shares worth $148. The position accounts for ﹤0.01% of the portfolio, ranked #4252.

Russell Investments Group first reported a position in LAB in Q4 2016 and has held it in 25 quarters since. The position peaked at $74.2M in Q1 2019. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Russell Investments Group held 180 shares of Standard BioTools worth $148 as of Q2 2026.
  • Russell Investments Group sold 21,454 Standard BioTools shares in Q2 2026, an estimated $20.3K.
  • Standard BioTools made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #4252 holding.
  • Russell Investments Group first reported a position in Standard BioTools in Q4 2016 and has held it in 25 quarters since.
  • Russell Investments Group's Standard BioTools position peaked at $74.2M in Q1 2019.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.